tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Dec 17;10(12):2174.
doi: 10.3390/vaccines10122174.
Peripheral Nervous System Adverse Events after the Administration of mRNA Vaccines: A Systematic Review and Meta-Analysis of Large-Scale Studies
Yu-Hsin Lai[SUP] 1 [/SUP], Hong-Yu Chen[SUP] 2 [/SUP], Hsin-Hui Chiu[SUP] 1 3 [/SUP], Yi-No Kang[SUP] 1 4 [/SUP], Shi-Bing Wong[SUP] 1 5 [/SUP]
Affiliations
Abstract
Although neurological complications after the administration of vaccines against coronavirus disease 2019 (COVID-19) are rare, they might result in long-term morbidity. This study was designed to determine the risk of peripheral nervous system (PNS) adverse events after the administration of mRNA vaccines against COVID-19. Large-scale randomized controlled trials (RCTs) and cohort studies were systematically searched in databases, and 15 cohort studies were included in the synthesis. Among all PNS adverse events, only Bell's palsy and Guillain-Barré syndrome (GBS) had sufficient data and were included for further analysis. Individuals who received mRNA vaccines had a higher risk of Bell's palsy than the unvaccinated group, and the risk of Bell's palsy after BNT162b2 was significantly higher than after mRNA-1273. Regarding GBS, no significant difference in the risk was observed between BNT162b2 and the unvaccinated group, but BNT126b2 introduced a higher risk of post-vaccinated GBS than mRNA-1273. In conclusion, PNS adverse events, especially Bell's palsy, should be carefully observed after mRNA vaccination against COVID-19. With the opportunity of vaccination campaigns on such a large scale, further investigation and surveillance of post-vaccination neurological adverse events should also be established.
Keywords: BNT162b2; Bell’s palsy; COVID-19; Guillain–Barré syndrome; mRNA-1273.
. 2022 Dec 17;10(12):2174.
doi: 10.3390/vaccines10122174.
Peripheral Nervous System Adverse Events after the Administration of mRNA Vaccines: A Systematic Review and Meta-Analysis of Large-Scale Studies
Yu-Hsin Lai[SUP] 1 [/SUP], Hong-Yu Chen[SUP] 2 [/SUP], Hsin-Hui Chiu[SUP] 1 3 [/SUP], Yi-No Kang[SUP] 1 4 [/SUP], Shi-Bing Wong[SUP] 1 5 [/SUP]
Affiliations
- PMID: 36560584
- DOI: 10.3390/vaccines10122174
Abstract
Although neurological complications after the administration of vaccines against coronavirus disease 2019 (COVID-19) are rare, they might result in long-term morbidity. This study was designed to determine the risk of peripheral nervous system (PNS) adverse events after the administration of mRNA vaccines against COVID-19. Large-scale randomized controlled trials (RCTs) and cohort studies were systematically searched in databases, and 15 cohort studies were included in the synthesis. Among all PNS adverse events, only Bell's palsy and Guillain-Barré syndrome (GBS) had sufficient data and were included for further analysis. Individuals who received mRNA vaccines had a higher risk of Bell's palsy than the unvaccinated group, and the risk of Bell's palsy after BNT162b2 was significantly higher than after mRNA-1273. Regarding GBS, no significant difference in the risk was observed between BNT162b2 and the unvaccinated group, but BNT126b2 introduced a higher risk of post-vaccinated GBS than mRNA-1273. In conclusion, PNS adverse events, especially Bell's palsy, should be carefully observed after mRNA vaccination against COVID-19. With the opportunity of vaccination campaigns on such a large scale, further investigation and surveillance of post-vaccination neurological adverse events should also be established.
Keywords: BNT162b2; Bell’s palsy; COVID-19; Guillain–Barré syndrome; mRNA-1273.